Elsevier

The Lancet

Volume 376, Issue 9740, 14–20 August 2010, Pages 495-496
The Lancet

Comment
After CAPRISA 004: time to re-evaluate the HIV lexicon

https://doi.org/10.1016/S0140-6736(10)61200-7Get rights and content

References (7)

There are more references available in the full text version of this article.

Cited by (29)

  • Contextual Factors Associated with Sexually Transmitted Infections

    2012, Sexually Transmitted Diseases: Vaccines, Prevention, and Control
  • Genital and Perinatal Herpes Simplex Virus Infections

    2012, Sexually Transmitted Diseases: Vaccines, Prevention, and Control
  • Microbicides: Still a long road to success

    2012, Trends in Microbiology
    Citation Excerpt :

    In general, to date, more than 70 preclinical microbicide trials and 50 clinical trials of different phases have been performed (see www.microbicide.org). One of the important and unexpected results of CAPRISA 004 was a significant 51% reduction of the rate of acquisition of HSV-2, a common HIV-1 copathogen which facilitates HIV-1 transmission [54]. This effect was not anticipated, because in in vitro studies tenofovir showed no anti-HSV activity at the concentrations corresponding to systemic administration [55], whereas higher concentrations were considered to be nonphysiological.

  • Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication

    2011, Cell Host and Microbe
    Citation Excerpt :

    Tenofovir convincingly diminished HIV-1 transmission (by 39%). Surprisingly, in the CAPRISA 004 trial, a significant 51% reduction of the risk of acquiring HSV-2, a common HIV-1 copathogen that facilitates HIV transmission, was also observed (Cates, 2010). This effect of tenofovir gel on HSV was rather unanticipated because this highly potent antiretroviral and antihepadnaviral drug has been previously shown to exhibit minimal, if any, anti-HSV activity (Balzarini et al., 1993).

View all citing articles on Scopus
View full text